Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$4.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$4.00 (80)
Ask (Size)$4.60 (2)
Day Low / HighN/A - N/A
Volume394.6 K
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $4.30
Change: +0.15 (3.61%)
Volume: 394.6 K
4:00PM ET 7/01/2022
 
 

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $1.25
Change: +0.12 (10.62%)
Volume: 5.0 M
4:00PM ET 7/01/2022
 
 

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $3.80
Change: -0.19 (4.76%)
Volume: 579.7 K
4:00PM ET 7/01/2022
 
 

Verastem Inc ( NASDAQ )

Price: $1.13
Change: -0.03 (2.59%)
Volume: 2.1 M
4:00PM ET 7/01/2022
 
 

VBI Vaccines Inc ( NASDAQ )

Price: $0.81
Change: -0.0001 (0.01%)
Volume: 984.9 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Rhythm Pharmaceuticals Rolls Out Weight-Loss Drug Imcivree in Germany
9:06AM ET 6/22/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Wednesday that it has launched weight-loss drug Imcivree in Germany. Imcivree received European Commission approval last...

Rhythm Pharmaceuticals Gets European Commission Approval for Expansion of Imcivree Dosing Regimen
8:39AM ET 6/22/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) said Wednesday the European Commission approved the expansion of the dosing regimen for its Imcivree drug. The approval...

Needham Adjusts Rhythm Pharmaceuticals' Price Target to $25 From $40, Keeps Buy Rating
8:54AM ET 6/17/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $4 to $40, according to analysts polled by Capital IQ. (MT...

Stifel Adjusts Price Target on Rhythm Pharmaceuticals to $25 From $23, Reiterates Buy Rating
7:33AM ET 6/17/2022 MT Newswires

Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $4 to $40, according to analysts polled by Capital IQ. (MT...

View all Commentary and Analysis

Tracking Baker Brothers Portfolio - Q1 2022 Update
3:07AM ET 7/01/2022 Seeking Alpha

Rhythm Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
2:49PM ET 5/03/2022 Seeking Alpha

Rhythm Pharmaceuticals (RYTM) Investor Presentation - Slideshow
12:18PM ET 4/13/2022 Seeking Alpha

Tracking Baker Brothers Portfolio - Q4 2021 Update
10:10PM ET 3/30/2022 Seeking Alpha

Company Profile

Business DescriptionRhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. View company web site for more details
Address222 Berkeley Street
Boston, Massachusetts 02116-3748
Phone+1.857.264.4280
Number of Employees54
Recent SEC Filing06/16/20228-K
Chairman, President & Chief Executive OfficerDavid P. Meeker
Chief Financial Officer & TreasurerHunter C. Smith
Vice President-Medical AffairsBrieana Buckley
Chief Technical OfficerJoseph Shulman

Company Highlights

Price Open$4.08
Previous Close$4.15
52 Week Range$3.04 - 20.81
Market Capitalization$216.7 M
Shares Outstanding50.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.30
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-3,598.16%
Return on Equity-55.66%

Analyst Ratings as of 03/04/2022

Buy
6
Overweight
0
Hold
2
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset